Cobenfy is the first drug to treat the disease that targets the brain's cholinergic receptors
Washington: The US Food and Drug Administration has approved a new drug for adults with schizophrenia.
The drug, commonly known as Cobenfy, is the first drug to treat the disease that targets the brain's cholinergic receptors, rather than the dopamine receptors that are the traditional focus of treatment.
“Schizophrenia is the leading cause of disability worldwide,” said Dr. Tiffany Farshion in the Institute's Department of Neuroscience.
He stated the drug represents the first new approach to treating schizophrenia. It offers a new alternative to the antipsychotic drugs that have previously been prescribed to people with schizophrenia.
It is pertinent to note that schizophrenia is a severe, chronic mental illness that often impairs a person's quality of life.
The false promise of a “no sugar” diet
- 4 گھنٹے قبل
The most important line from Trump’s State of the Union
- 4 گھنٹے قبل
Stars' Rantanen out weeks after Olympic injury
- 5 گھنٹے قبل
FTC declines to enforce a kids privacy law for data collected to verify users’ ages
- 6 گھنٹے قبل
Can you fix a broken democracy without breaking it more?
- 4 گھنٹے قبل
Dodgers' Sasaki hit hard, struggles in spring debut
- 5 گھنٹے قبل
The Pentagon’s battle with Anthropic is really a war over who controls AI
- 4 گھنٹے قبل
Everyone ignores this good news about democracy
- 4 گھنٹے قبل
Lightning's Cooper out 2 games after dad's death
- 5 گھنٹے قبل
Brazil vs. US: Two insurrections, different results
- 4 گھنٹے قبل
Netflix’s F1 series Drive to Survive will stream on Apple TV, too
- 6 گھنٹے قبل
Cricut’s most popular cutting machine now takes up less space in your crafting room
- 6 گھنٹے قبل
